Ketamine IV in Spain: Prices, Indications & Authorised Clinics

Ketamine is a dissociative anaesthetic that at sub-anaesthetic doses acts as an NMDA receptor antagonist, producing rapid-onset (within hours) antidepressant, anxiolytic and neuroplastic effects. IV ketamine infusion at 0.5 mg/kg over 40 minutes is the standard for treatment-resistant depression. In longevity and mental health, its potential for neuroplasticity, PTSD treatment, chronic anxiety and chronic pain is actively investigated.

Origin and history

Ketamine was synthesised by Calvin Stevens in 1962 and FDA-approved as an anaesthetic in 1970. Its antidepressant use was discovered serendipitously in the late 1990s. The first controlled studies of IV infusion for depression were published by the NIMH in 2006, marking a milestone in psychopharmacology.

1. Psychiatric evaluation Diagnosis of treatment-resistant depression (2+ failed antidepressants). Exclusion of active psychosis and hypertension.

2. Preparation and monitoring 4-hour fast. Peripheral IV access. BP, HR and SpO₂ monitoring. Calm, dimly lit environment.

3. Ketamine infusion 0.5 mg/kg IV over 40 min via controlled infusion pump. Medical staff present throughout.

4. Integration period 15–30 min post-infusion rest. Psychological support. Experience journaling.

5. 6-session protocol 3 infusions/week for 2 weeks. Post-protocol response evaluation. Monthly maintenance.

• The fastest-acting antidepressant known (hours versus weeks)
• Effective in depression resistant to multiple drugs
• Rapid reduction of suicidal ideation
• Effects on treatment-refractory PTSD, anxiety and OCD
• Stimulation of neurogenesis and neuroplasticity
• Efficacy in chronic neuropathic pain and CRPS

• 1People with major depression resistant to 2+ antidepressants
• 2Patients with active suicidal ideation (emergency response)
• 3People with severe refractory PTSD
• 4Patients with chronic neuropathic pain or CRPS
• 5Those seeking supervised therapeutic consciousness expansion

• Active psychosis or schizophrenia
• Uncontrolled hypertension (ketamine raises blood pressure)
• History of ketamine or other dissociative abuse
• Pregnancy

Clinics on LongevityMap declare their exact equipment for objective scoring.

€300–600 per infusion

6 infusions over 2–3 weeks (initial protocol); monthly maintenance

Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.

The FDA approved intranasal esketamine (Spravato) in 2019 for treatment-resistant depression. Studies from the Yale Mood Disorders Research Program confirm antidepressant response in 70% of patients with treatment-resistant depression after IV infusions. The mechanism includes NMDA antagonism, AMPA/mTOR activation and rapid synapse formation in the prefrontal cortex. Effects on BDNF and prefrontal synapses persist beyond the drug's presence in the body.